Distribution Agreement in Saudi Arabia and Jordan
News Jul 10, 2015
RaySearch Laboratories AB (publ.) has entered into a long-term distribution agreement with Trading Medical Systems Jordan (TMSJ) in Amman, Jordan. According to the agreement, TMSJ assumes full responsibility for the marketing, sales and service of RaySearch’s treatment planning system, RayStation®, in the markets of Saudi Arabia and Jordan.
TMSJ is a leading distributor of medical equipment used in the treatment of cancer and represents a wide range of respected international suppliers. The company was founded in 1995 and is well established in the radiation therapy, radiology and dosimetry market in Jordan with a dedicated and highly experienced sales and support team.
“TMSJ is honored to be representing RaySearch, that has a distinguished reputation to deliver highly innovative treatment planning solutions, in Saudi Arabia and Jordan. We are looking forward to promoting RayStation® to our customers in the region”, says Faris Al-Said, CEO of Trading Medical Systems Jordan.
“RayStation® is established as a world leading treatment planning system for radiation therapy and so far it has been sold to 20 different countries. We are excited to work with such an experienced partner as TMSJ to introduce RayStation® in Saudi Arabia and Jordan in order to serve customers in those countries in the best possible way”, says Johan Löf, CEO of RaySearch.
Single Blood Test 'CancerSEEK' Screens for Eight Cancer TypesNews
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.READ MORE
Small Compound Able to Stave Tumor and Stop its GrowthNews
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital nutrient glutamine.READ MORE
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE